Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center of Postgraduate Education, European Health Centre, Otwock, Poland.
Department of Radiology, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
Chest. 2012 Dec;142(6):1406-1416. doi: 10.1378/chest.11-2794.
Right ventricular failure does not explain all cases of death in patients with chronic pulmonary hypertension. Searching for alternative explanations, we evaluated the prognostic significance of main pulmonary artery (PA) dilatation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
A retrospective outcome analysis was made of 264 patients (aged 46 ± 17 years; women, 69%; PAH, 82%) who underwent both CT scan measurement of the PA and right-sided heart catheterization (mean PA pressure, 57.6 ± 16.5 mm Hg) at initial evaluation.
The diameter of the PA ranged from 28 to 120 mm (mean, 39 ± 8.6 mm; median, 38 mm) and was largest in patients with unrepaired congenital defects (42.6 ± 7.6 mm). Pulmonary pulse pressure (P = .04), lower age (P = .03), and duration of symptoms (P < .001) were independently but weakly related to PA diameter. During follow-up (median, 38 months), 99 patients (37%) died. Of these 99 deaths, 73 (74%) were due to heart failure or comorbidities, and 26 (26%) were unexpected deaths (UE-Ds). PA diameter (hazard ratio [HR], 1.06 per 1 mm; 95% CI, 1.03-1.08), heart rate (HR, 1.30 per 10 beats/min; 95% CI, 1.01-1.66), and systolic pulmonary arterial pressure (HR, 1.02 per 1 mm Hg; 95% CI, 1.01-1.04) were the only independent predictors of UE-D and differed from the usual predictors found in the study group for all-cause mortality. PA diameter ≥ 48 mm had 95% specificity and 39% sensitivity and carried 7.5 times higher risk of UE-D (95% CI, 3.4-16.5; P < .0001) during follow-up.
PA dilatation emerges as an independent risk factor for death unexplained by right ventricular failure or comorbidities in patients with PAH and CTEPH. The possible mechanisms include, but are not limited to, PA compression of the left main coronary artery, PA rupture, or dissection with cardiac tamponade.
右心衰竭并不能解释所有慢性肺动脉高压患者的死亡病例。为寻找其他解释,我们评估了主肺动脉(PA)扩张在肺动脉高压(PAH)或慢性血栓栓塞性肺动脉高压(CTEPH)患者中的预后意义。
对 264 名(年龄 46 ± 17 岁;女性占 69%;PAH 占 82%)接受 CT 扫描测量 PA 和右心导管检查(平均 PA 压 57.6 ± 16.5 mm Hg)的患者进行回顾性预后分析。
PA 直径范围为 28 至 120 mm(平均值 39 ± 8.6 mm;中位数 38 mm),在未修复的先天性缺陷患者中最大(42.6 ± 7.6 mm)。肺脉搏压(P =.04)、较低的年龄(P =.03)和症状持续时间(P <.001)与 PA 直径独立但弱相关。在随访期间(中位数 38 个月),99 名患者(37%)死亡。这 99 例死亡中,73 例(74%)归因于心力衰竭或合并症,26 例(26%)为意外死亡(UE-D)。PA 直径(风险比[HR],每增加 1 毫米 1.06;95%CI,1.03-1.08)、心率(HR,每增加 10 次/分钟 1.30;95%CI,1.01-1.66)和收缩期肺动脉压(HR,每增加 1 mm Hg 1.02;95%CI,1.01-1.04)是 UE-D 的唯一独立预测因素,与研究组全因死亡率的常用预测因素不同。PA 直径≥48 mm 具有 95%的特异性和 39%的敏感性,在随访期间 UE-D 的风险增加 7.5 倍(95%CI,3.4-16.5;P <.0001)。
PA 扩张是 PAH 和 CTEPH 患者右心衰竭或合并症无法解释的死亡的独立危险因素。可能的机制包括但不限于 PA 对左主冠状动脉的压迫、PA 破裂或夹层伴心脏压塞。